Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — Ra Medical Systems — IPO Roadshow (January 2022)
21 slides from Catheter Precision's IPO roadshow presentation, Jan 28, 2022
Slide 1: Ra Medical Systems Corporate Presentation January 2022
Filed pursuant to Rule 433 under the Securities Act of 1933, as amended Dated 1/28/22 Registration Statement No. 333-262195 Ra Medical TM SYSTEMS Ra Medical Systems, Inc. NYSE American: RMED Corporate Presentation January 2022
Slide 2: Disclaimer
Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Ra Medical Systems, Inc. (the “Company”) and involve known and unknown risks, uncertainties and othe
Slide 3: Free Writing Prospectus
Free Writing Prospectus This presentation highlights basic information about us and the offering. Because it is a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should consider before investing in the Company. Except as otherwise
Slide 4: Risk Factors
Risk Factors This presentation highlights basic information about us and the offering. Because it is a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should consider before investing in the Company. Except as otherwise indicated,
Slide 5: Ra Medical Overview
Ra Medical Overview Targeting markets with strong reimbursement and where our technology can help save lives and limbs Clearances FDA 510(k) Crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease CE mark Endovascular treatment of infrainguinal a
Slide 6: Differentiated DABRA Technology
Differentiated DABRA Technology DABRA Catheter • Liquid-filled catheter • Designed to track the true lumen • 94% effectiveness (as measured by successful crossing of target lesion) • Low cost 308 nm Excimer Laser • Portable • Easy to maneuver • Low customer acquisition cost Photoablation Mechanism o
Slide 7: Key Efforts Underway to Drive Future Growth and Expansion
Key Efforts1 Underway to Drive Future Growth and Expansion Extended shelf life • Data obtained to support 6-month shelf life • Work in process to generate data supporting up to 12-month shelf life DABRA 2.0 • A more robust catheter with an enhanced outer-jacket, to provide greater trackability and k
Slide 8: DABRA Catheter Engineering Programs
DABRA Catheter Engineering Programs DABRA 2.0 CTO catheter with improved deliverability and robustness • A next-generation catheter with an enhanced outer-jacket designed to allow physicians to better access difficult anatomy • Targeting Q1 2022 510(k) submission DABRA RX catheter that is compatible
Slide 9: Expanded Indication: Atherectomy
Expanded Indication: Atherectomy U.S. Pivotal Clinical Trial Underway: • 7 sites cleared to enroll; 90 subjects enrolled as of January 14, 2022 • Estimated enrollment completion mid-year 2022 with 6-month follow-up completed by year-end 20221 Study size: • Up to 10 sites, 100 subjects2 Primary effic
Slide 10: Anticipated Ra Medical Milestones
Anticipated Ra Medical Milestones • DABRA 2.0 CTO (with 6- month shelf life) FDA 510(k) submission • Atherectomy study protocol amendment FDA cleared for additional 25 subjects • Atherectomy study enrollment completion (mid-year ’22) • Submit upgraded Laser 510(k) • Finalize DABRA RX design (mid-yea
Slide 11: Peripheral Artery Disease
Peripheral Artery Disease1 Disease Prevalence and Burden • An estimated 19-21 million people suffer from PAD in the US resulting in up to 200,000 lower limb amputations annually2,3 Disease Overview • Atherosclerosis of the lower extremities—most commonly in the legs • Smoking, genetic predisposition
Slide 12: US Peripheral Atherectomy Market Overview
12 US Peripheral Atherectomy Market Overview1 1Medtech360. Peripheral Vascular Devices -Marketing Insights –US -2021. Published September 2020. Philips, 22% Boston Scientifc, 14% CSI, 33% Medtronic, 31% Other, 1% Estimated 2019 Atherectomy Revenue Market Share $720 $730 $740 $750 $760 $770 $780 2022
Slide 13: Laser and catheter comparison
13 Laser size 27” L x 39” H x 19” W 49” L x 35” H x 24” W29” L x 37” H x 13.3” W Laser weight 172-179 lbs 650 lbs 198 lbs Energy wavelength 308 nm 308 nm 355 nm Catheter design Liquid filled Fused silica fiber optic bundle Fused silica fiber optic bundle Ablative surface Full aperture ablative surfa
Slide 14: Market Opportunity for DABRA: Initial Focus Office-Based Labs
14 •Office-Based Labs (OBL) segment represents a growing % of PAD and atherectomy procedures •Established, strong reimbursement •Physicians in OBL open to new products that enable improved results and greater efficiency •Price sensitive •Lower barrier to entry Market Opportunity for DABRA Initial Fo
Slide 15: What is Intravascular Lithotripsy?
15 What is Intravascular Lithotripsy? •The use of shockwaves of sufficient magnitude to fracture calcium in coronary or peripheral arteries NASDAQ:SWAV $4.7B market cap2 2021E Rev3: $227M -$228M Adjacent Market: Intravascular Lithotripsy Benefits •Increases compliance of coronary or peripheral arter
Slide 16: Capitalization
16 Capitalization Common Stock Equivalents Balance Sheet and Capitalization As of Sept 30, 2021 Cash $20.6M Debt (excluding operating leases) $0 Common Stock 7,005,367 Warrants (WAEP$9.64) 2,419,280 Options (WAEP$345.54) 126,998 RSUs 45,832 Total Fully Diluted 9,597,477 Ra Medical TM SYSTEM
Slide 17: Appendix
17 Appendix Ra Medical TM SYSTEM
Slide 18: DABRA Clinical Study for Initial FDA Clearance
18 0 10 20 30 40 50 60 70 80 90 100 94% 1The pivotal study formed the basis of our May 24, 2017 510(k) clearance. 2For information on how we defined device-related SAEs for purposes of our pivotal study, see https://clinicaltrials.gov/ct2/show/study/NCT02653456 Efficacy Overview •Multi-site pivotal
Slide 19: Management Team
19 Management Team Will McGuire Chief Executive Officer 25 years med-tech experience, including COO of Spectranetics which was acquired by Philips for >$2 billion and CEO of Atheromed, a venture capital-backed peripheral atherectomy company. Also held senior roles at Volcano Corporation, Covidien, a
Slide 20: Board of Directors
20 Board of DirectorsMartin Colombatto Chairman Former VP and General Manager of Broadcom Will McGuire Chief Executive Officer, Ra Medical Former CEO Second Sight, former executive at Covidien, AtheroMed, Spectranetics Richard Mejia Former Partner of Ernst & Young Susanne Meline Co-founder of Franci
Slide 21: Current PAD Treatments and Limitations
21 Current PAD Treatments and Limitations Non-Invasive Management Lifestyle Changes •Often hard to sustain Pharmacotherapy •Generally prescribed for life and does not treat the obstruction, making them ineffective for many •More aggressive treatments often required Interventional Procedures Angiopla